Literature DB >> 21886153

Cancer: Tumour-fighting virus homes in.

Evanthia Galanis.   

Abstract

Mesh：

Year:  2011        PMID： 21886153     DOI： 10.1038/477040a

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  9 in total

1.  Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors.

Authors:  Benjamin Diop-Frimpong; Vikash P Chauhan; Stephen Krane; Yves Boucher; Rakesh K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-31       Impact factor: 11.205

Review 2.  Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress.

Authors:  Ta-Chiang Liu; Evanthia Galanis; David Kirn
Journal:  Nat Clin Pract Oncol       Date:  2007-02

3.  Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.

Authors:  Caroline J Breitbach; James Burke; Derek Jonker; Joe Stephenson; Andrew R Haas; Laura Q M Chow; Jorge Nieva; Tae-Ho Hwang; Anne Moon; Richard Patt; Adina Pelusio; Fabrice Le Boeuf; Joe Burns; Laura Evgin; Naomi De Silva; Sara Cvancic; Terri Robertson; Ji-Eun Je; Yeon-Sook Lee; Kelley Parato; Jean-Simon Diallo; Aaron Fenster; Manijeh Daneshmand; John C Bell; David H Kirn
Journal:  Nature       Date:  2011-08-31       Impact factor: 49.962

4.  Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice.

Authors:  Timothy Kottke; Geoff Hall; Jose Pulido; Rosa Maria Diaz; Jill Thompson; Heung Chong; Peter Selby; Matt Coffey; Hardev Pandha; John Chester; Alan Melcher; Kevin Harrington; Richard Vile
Journal:  J Clin Invest       Date:  2010-04-01       Impact factor: 14.808

5.  Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus.

Authors:  D F Stojdl; B Lichty; S Knowles; R Marius; H Atkins; N Sonenberg; J C Bell
Journal:  Nat Med       Date:  2000-07       Impact factor: 53.440

6.  Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis.

Authors:  Thi Lien-Anh Nguyên; Hesham Abdelbary; Meztli Arguello; Caroline Breitbach; Simon Leveille; Jean-Simon Diallo; Amber Yasmeen; Tarek A Bismar; David Kirn; Theresa Falls; Valerie E Snoulten; Barbara C Vanderhyden; Joel Werier; Harold Atkins; Markus J V Vähä-Koskela; David F Stojdl; John C Bell; John Hiscott
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-24       Impact factor: 11.205

7.  Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.

Authors:  Neil N Senzer; Howard L Kaufman; Thomas Amatruda; Mike Nemunaitis; Tony Reid; Gregory Daniels; Rene Gonzalez; John Glaspy; Eric Whitman; Kevin Harrington; Howard Goldsweig; Tracey Marshall; Colin Love; Robert Coffin; John J Nemunaitis
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

8.  Vaccinia virus intermediate stage transcription is complemented by Ras-GTPase-activating protein SH3 domain-binding protein (G3BP) and cytoplasmic activation/proliferation-associated protein (p137) individually or as a heterodimer.

Authors:  George C Katsafanas; Bernard Moss
Journal:  J Biol Chem       Date:  2004-10-06       Impact factor: 5.157

9.  Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection.

Authors:  Kara L Norman; Kensuke Hirasawa; An-Dao Yang; Michael A Shields; Patrick W K Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-19       Impact factor: 11.205
  9 in total
  3 in total

Review 1.  Targeted entry of enveloped viruses: measles and herpes simplex virus I.

Authors:  Chanakha K Navaratnarajah; Tanner S Miest; Andrea Carfi; Roberto Cattaneo
Journal:  Curr Opin Virol       Date:  2011-12-23       Impact factor: 7.090

Review 2.  Promoter-Operating Targeted Expression of Gene Therapy in Cancer: Current Stage and Prospect.

Authors:  Chao Chen; Dongxu Yue; Liangyu Lei; Hairong Wang; Jia Lu; Ya Zhou; Shiming Liu; Tao Ding; Mengmeng Guo; Lin Xu
Journal:  Mol Ther Nucleic Acids       Date:  2018-04-12       Impact factor: 8.886

3.  Survivin promoter-regulated oncolytic adenovirus with Hsp70 gene exerts effective antitumor efficacy in gastric cancer immunotherapy.

Authors:  Weiguo Wang; Weidan Ji; Huanzhang Hu; Juming Ma; Xiaoya Li; Weiqun Mei; Yang Xu; Huizhen Hu; Yan Yan; Qizhe Song; Zhigang Li; Changqing Su
Journal:  Oncotarget       Date:  2014-01-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.